Brevinin-2DYb
General Information
DCTPep ID DCTPep01057
Peptide Name Brevinin-2DYb
Sequence GLFDVVKGVLKGAGKNVAGSLLEQLKCKLSGGC
Sequence Length 33
UniProt ID Not available
PubChem CID Not available
Origin Rana dybowskii
Type Native peptide
Classification
ACP Tumor active peptide
Activity Information
Cell Line | Disease | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|
HeLa | Human papillomavirus-related endocervical adenocarcinoma | IC50=23.26 µM | MTT assay | 24h | 1 |
A549 | Lung adenocarcinoma | IC50=24.01 µM | MTT assay | 24h | 1 |
LoVo | Colon adenocarcinoma | IC50=35.05 µM | MTT assay | 24h | 1 |
MCF-7 | Invasive breast carcinoma of no special type | IC50=37.84 µM | MTT assay | 24h | 1 |
Hemolytic Activity Sheep erythrocytes: <10% Hemolysis=256 µM
Normal (non-cancerous) Cytotoxicity HEK293T cells: IC50=50.66 µM
Target Not available
Affinity Not available
Mechanism Not available
Structure Information
PDB ID Not available
Predicted Structure DCTPep01057
(Please note that there is the predicted structure, predicted by AlphaFold)
Helicity Not available
Linear/Cyclic Cyclic
Disulfide/Other Bond Cys27<--->Cys33
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C145H250N40O42S2
Absent amino acids HIMPRTWY
Theoretical pI 9.24
Acidic residues 2
Basic residues 5
Polar residues 12
Molecular weight (Average) 3289.94
Molecular weight (Monoisotopic) 3287.81
Common amino acids G
Net charge 3
Instability index (II) 4.13
Aliphatic index 112.12
Grand average of hydropathicity (GRAVY) 0.397
Half Life
30 hours (mammalian reticulocytes, in vitro).
>20 hours (yeast, in vivo).
>10 hours (Escherichia coli, in vivo).
Extinction coefficients
Ext. coefficient 125
Abs 0.1% (=1 g/l) 0.038, assuming all pairs of Cys residues form cystines
Ext. coefficient 0
Abs 0.1% (=1 g/l) 0.000, assuming all Cys residues are reduced
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 34073203
Title Prediction of Anticancer Peptides with High Efficacy and Low Toxicity by Hybrid Model Based on 3D Structure of Peptides
Year 2021
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available